This cost-effectiveness analysis compares nivolumab plus ipilimumab vs sunitinib to examine whether the drug combination is cost-effective from a US payer perspective as a first-line treatment for intermediate- and poor-risk patients with metastatic renal cell carcinoma.
https://ift.tt/2E64gZ4
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου